SABS icon

SAB Biotherapeutics

37 hedge funds and large institutions have $92.7M invested in SAB Biotherapeutics in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
37
Holders Change
+11
Holders Change %
+42.31%
% of All Funds
0.65%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
15
Increased
6
Reduced
7
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Shares
Change %
CM
26
Crestline Management
Texas
$505K +$505K +5,061 New
DWM
27
Dakota Wealth Management
Florida
$504K +$504K +5,058 New
Citadel Advisors
28
Citadel Advisors
Florida
$382K -$77.5K -777 -17%
Millennium Management
29
Millennium Management
New York
$365K +$365K +3,666 New
Jane Street
30
Jane Street
New York
$359K +$174K +1,748 +94%
JPMorgan Chase & Co
31
JPMorgan Chase & Co
New York
$269K
EAM
32
Exos Asset Management
New York
$249K -$399 -4 -0.2%
UBS Group
33
UBS Group
Switzerland
$15K +$6.18K +61 +70%
TRCT
34
Tower Research Capital (TRC)
New York
$1K +$1K +9 New
Walleye Capital
35
Walleye Capital
New York
$776 +$776 +7,793 New
MF
36
Magnetar Financial
Illinois
$140 +$140 +1,405 New
MP
37
Mangrove Partners
Connecticut
-$5.09M -51,838 Closed
WAM
38
Weiss Asset Management
Massachusetts
-$100K -1,019 Closed
HighTower Advisors
39
HighTower Advisors
Illinois
-$98K -1,000 Closed
Morgan Stanley
40
Morgan Stanley
New York
-$1K -13 Closed